FindTrial
Sign In

Observational study to assess correlation between gene present in DNA which cause fast or slow metabolism of drug (genotype), concentration of drug in blood (phenotype) and prakriti in patients on phenytoin monotherapy

A prospective, observational study to assess the correlation between phenotype, genotype and prakriti in patients on phenytoin monotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2011/06/001782
Enrollment
200
Registered
2011-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients who are on phenytoin monotherapy

Interventions

Intervention1: nil: nil

Sponsors

Investigator initiated study
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients who are on phenytoin monotherapy for prophylaxis or treatment since one month 2 Patients willing to give informed consent

Exclusion criteria

Exclusion criteria: 1 Age below 18 years 2 Patients with clinical H/o hepatic failure, renal failure, hypoalbuminemia, anaemia 3 Patients suffering from psychological disorder 4 Pregnant and lactating women 5 Patients of the same family 6 Patients taking drugs which induce or inhibit CYP2C9 and CYP2C19 enzymes

Design outcomes

Primary

MeasureTime frame
1.correlation between phenotype and genetic polymorphism of cyp2c9 and cyp2c19. 2. correlation between genetic polymorphism of cyp2c9 and cyp2c19 and prakriti. 3. correlation between penotype and genetic polymorphism of cyp2c9 and cyp2c19.Timepoint: 16 weeks—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr U M Thatte
drprajaktabasole@gmail.com9503925929

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026